At TCG Lifesciences (TCGLS), our In Vitro Pharmacology division supports the entire preclinical drug discovery journey. By combining deep expertise in molecular and cell biology with advanced assay development and screening technologies, we deliver reliable, high-quality data to make confident decisions while maintaining flexibility to support diverse project needs.
End-to-end capabilities across multiple therapeutic areas—including oncology, CNS disorders, inflammation, pain, metabolic diseases, and anti-infectives using biologically relevant models, along with cell line generation, assay development, high-throughput screening, and mechanism-of-action studies.
Molecular and cell biology services, including gene cloning, bacterial and mammalian protein expression, recombinant cell line development, access to 80+ cancer cell lines including diverse primary cells and extensive biochemical as well as cell-based assay platforms with diverse readouts, supported by high-content imaging and flow cytometry.
Reporter-based and inducible expression systems to investigate GPCRs, ion channels, receptor tyrosine kinases, and downstream signalling pathways.
Dedicated BSL-2 anti-infective screening platform covering drug-resistant bacteria, fungi, and parasites, including MIC/MFC, resistance profiling, synergy studies, PRR, MIR, biofilm assays, anti-candida profiling, and time-kill kinetics.
Scalable formats from manual bench assays to automated high-throughput screening, with flexible models including technology transfer, co-development, and customised assay execution to accelerate SAR support and lead optimisation.
Flexible, partnership-driven capabilities and commitment to precision & impact.
Our Core Capabilities
